



Uscom

ASX MEDIA RELEASE

Ten-Year China Patents Issued for USCOM 1A

Commercial Protection in China for Uscom's Flagship Cardiac Monitor

SYDNEY, Australia, Monday 8th November 2021: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) today announced the granting of two Chinese patents by the China National Intellectual Property Administration for its USCOM 1A cardiac output monitoring technology. The patent provides commercial competitive protection in the Chinese market for a period of 10 years. The two utility model patents are titled "Blood Flow Detection and Analysis Equipment Applicable to Ultrasonic Cardiac Output Monitor" and "Ultrasonic Sensor Modules of Ultrasonic Cardiac Output Monitor". Uscom also has active patents for the USCOM 1A in Europe, the USA and Australia.

Summary:

Patents add significant value to products and are used worldwide to protect new ideas and inventions from copying by competitors. China is actively encouraging local and foreign companies to develop IP applications and respect IP in the national and global marketplace, resulting in the number of Chinese patents increasingly dramatically. In 2020 alone 530,000 invention patents were authorised in China, while China's total valid number of invention patents reached 2.213m. In 2020, 5.761m trademarks were registered with 149,000 opposition cases being reviewed, a year-on-year increase of 64.7%. This willingness to file and prosecute IP and IP breaches demonstrates an increasing awareness of the value of IP in China and an increasing use of the law to protect valid commercial interests. Uscom China has been active in developing a China IP strategy and now have 34 trademarks and copyrights active in China, with these two USCOM 1A patents being the first issued China patents, with more in review. The non-invasive ultrasound Doppler hemodynamic monitoring (USCOM 1A) was recommended by the National Health and Medical Commission of the People's Republic of China as the preferred method for the management of serious and severe COVID-19. Uscom China was also recognised as a National High Technology Enterprise by a branch of the Ministry of Science and Technology (MOST) established to advance innovation and high technology industries in China.

Commentary:

Uscom Executive Chairman, Professor Rob Phillips said "These are our first issued Chinese patents, and it's appropriate that they are for our flagship USCOM 1A product. Importantly these patents have real value by providing commercial protection for our highest selling device in our largest world market for another 10 years. This patent underwrites Uscom's long term sales growth and provides a commercial rationale for the expansion of our USCOM 1A manufacturing capabilities in China. As a world-leading medical technology company, innovation is a part of Uscom's business and we currently have more than 50 active IP cases worldwide."

References:

<https://www.mondaq.com/china/patent/1042704/cnipa-released-statistics-of-2020>



Uscom

ASX MEDIA RELEASE

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks.

The USCOM 1A: A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom BP+ is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They require no calibration, are simple to disinfect, and are simple and accurate to use providing research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices can be coupled with mobile phone apps and proprietary SpiroSonic software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, occupational lung disease and monitoring of pulmonary therapeutic compliance.

VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators. All ventilators require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. VENTITEST and VENTITEST-S, based on advanced SpiroSonic technology provides a testing solution that provides for simple and accurate testing, archiving, analysis and reporting to optimise ventilation performance.

For more information, please visit: www.uscom.com.au

Uscom Contacts

Rob Phillips
Chairman

rob@uscom.com.au

Brett Crowley
Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.